Key facts
- This page summarizes Zhenyu Xu's Form 4 filing for SOPHiA GENETICS SA (SOPH).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2026, 17:35.
Zhenyu Xu - 05 Aug 2026 Form 4 Insider Report for SOPHiA GENETICS SA (SOPH)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- SOPH
- Reported as of
- 05 Aug 2026
- Net transaction value
- -$144,924
- SEC form
- 4
- Accepted by SEC
- 07 Aug 2026, 17:35:27 UTC
- Prior SEC filing
- 05 Aug 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Zhenyu Xu filed Form 4 for SOPHiA GENETICS SA (SOPH) on 07 Aug 2026.
Change
- Previous filing in this sequence was filed on 05 Aug 2026.
- Current net transaction value: -$144,924.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002006362
Primary reporting owner
Xu Zhenyu
- Relationship
- Chief Scientific Officer
- Address
- C/O SOPHIA GENETICS SA, LA PIECE 12, ROLLE, SWITZERLAND
- Signature
- /s/ Elimara Brunetto as Attorney-in-fact for Zhenyu Xu
- Signature date
- 07 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SOPH
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +3,000
- Change %
- +0.5%
- Price
- $3.28*
- Shares after
- 603,887
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
SOPH
transaction
Ordinary Shares
Sale
- Transaction value
- $21,013
- Shares
- -3,000
- Change %
- -0.5%
- Price
- $7.00
- Shares after
- 600,887
- Date
- 05 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
SOPH
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +7,000
- Change %
- +1.2%
- Price
- $3.28*
- Shares after
- 607,887
- Date
- 07 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
SOPH
transaction
Ordinary Shares
Sale
- Transaction value
- $49,152
- Shares
- -7,000
- Change %
- -1.2%
- Price
- $7.02
- Shares after
- 600,887
- Date
- 07 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
SOPH
transaction
Ordinary Shares
Sale
- Transaction value
- $74,759
- Shares
- -10,000
- Change %
- -1.7%
- Price
- $7.48
- Shares after
- 590,887
- Date
- 07 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SOPH
transaction
Derivative
Share Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,000
- Change %
- -30%
- Price
- $3.28*
- Shares after
- 7,000
- Date
- 05 Aug 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,000
- Exercise price
- $3.28
- Footnotes
- F1, F4, F5
SOPH
transaction
Derivative
Share Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -7,000
- Change %
- -100%
- Price
- $3.28*
- Shares after
- 0
- Date
- 07 Aug 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 7,000
- Exercise price
- $3.28
- Footnotes
- F4, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 6 footnotes
Footnote F1
Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.08, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.40 to $7.56, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The share options are fully vested and exercisable.
Footnote F5
Following the transaction reported on this line, the Reporting Person holds an aggregate total of 982,041 derivative share options across all remaining grant tranches with varying exercise prices.
Footnote F6
Following the transaction reported on this line, the Reporting Person holds an aggregate total of 975,041 derivative share options across all remaining grant tranches with varying exercise prices.